SENTARA COMMUNITY PLAN
(MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-844-305-2331**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed**.

Drug Requested: Simponi® ARIA™ (golimumab) **(J1602) (Medical) (Non-Preferred)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

❑ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

DIAGNOSIS: Check diagnosis below that applies

❑ **Diagnosis – Moderate-to severe Active Rheumatoid Arthritis**
Dosage: IV: 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter (in combination with methotrexate)

❑ Member is 18 years of age or older

(Continued on next page)

- ❑ Member has a diagnosis of moderate to severe active rheumatoid arthritis
- ❑ Member had a trial and failure of one conventional synthetic disease modifying anti-rheumatic drug (csDMARD) (e.g. methotrexate, azathioprine, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.)
- ❑ Member has trial and failure of **BOTH** preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

❑ **Diagnosis – Active Psoriatic Arthritis**
Dosage: IV: Children ≥2 years and Adolescents: Simponi Aria: IV: 80 mg/m2/dose at weeks 0, 4, and then every 8 weeks thereafter. **Adults:** IV: 2 mg/kg at weeks 0, 4, and then every 8 weeks

- ❑ Member is 2 years of age or older
- ❑ Member has a diagnosis of psoriatic arthritis
- ❑ Member has trial and failure of **TWO (2)** preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®	❑ Pyzchiva® **OR** Starjemza™ syringe/vial (Requires trial and failure of a preferred TNF-alpha inhibitor)

❑ **Diagnosis – Active Ankylosing Spondylitis**
Dosage: IV: 2 mg/kg at weeks 0, 4, and then every 8 weeks thereafter

- ❑ Member is 18 years of age or older
- ❑ Member has a diagnosis of active ankylosing spondylitis
- ❑ Trial and failure of **BOTH** preferred drugs below

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

❑ **Diagnosis – Active Polyarticular Juvenile Idiopathic Arthritis**
Dosage: IV: 80 mg/m2/dose at weeks 0, 4, and then every 8 weeks thereafter

- ❑ Member is 2 years of age and older
- ❑ Member has a diagnosis of moderate to severely active juvenile rheumatoid arthritis OR juvenile idiopathic arthritis
- ❑ Member has at least five swollen joints
- ❑ Member has three or more joints with limitation of motion and pain, tenderness or both

(Continued on next page)

- ❑ Member has a trial and failure of either oral non-steroidal anti-inflammatory drugs (NSAIDs) OR one conventional synthetic disease modifying anti-rheumatic drug (csDMARD) (e.g. methotrexate, azathioprine, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.)
- ❑ Trial and failure of **BOTH** of the preferred drugs below:

❑ adalimumab-adbm (Boehringer Ingelheim) **OR** Hadlima® (adalimumab-bwwd)	❑ Enbrel®

Medication being provided by: Please check applicable box below.

- ❑ **Location/site of drug administration:** _____

  NPI or DEA # of administering location: _____

  OR

- ❑ **Specialty Pharmacy – PropriumRx**

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

Approved by Pharmacy and Therapeutics Committee: 1~~/16/2014~~; **11/19/2020**
REVISED/UPDATED/REFORMATTED: ~~1/27/2014; 2/7/2014; 4/4/2014; 4/28/2014; 10/31/2014; 4/3/2015; 5/23/2015; 12/23/2015; 1/29/2016; 9/28/2016; 12/11/2016; 7/24/2017; 1/1/2018; 3/28/2018; 4/30/2018; 11/23/2018; 3/19/2019; 5/5/2019; 7/8/2019;9/28/2019; 10/9/2019; 11/19/2020; 3/15/2021; 7/11/2022;6/26/2023, 10/17/2025: 12/21/2025, 2/24/2026; 3/11/2026;~~ **7/13/2026**